Q2050 — Doxorubicin, Pegylated Liposomal 2 Mg/ml Intravenous Suspension
$11,526
All-payer median here
$12,807
Cash / self-pay here
18
payer/plan-name variants
Median over current-blob negotiated rates (COALESCE of standard / median / min–max midpoint, $0.01–$5M sentinel guard). Payers are canonical-grouped where a mapping exists; unmapped regional-plan name variants may appear as separate rows.